Equity method investment ownership percentage maximum.

No definition available.

Name:	biib_EquityMethodInvestmentOwnershipPercentageMaximum
Namespace Prefix:	biib_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Method Investments, Expected Profit Share

+ References

No definition available.

+ Details

Name:	biib_EquityMethodInvestmentsExpectedProfitShare
Namespace Prefix:	biib_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Investments by third party in joint venture as per agreement

+ References

No definition available.

+ Details

Name:	biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Joint venture owner ship percentage by third party.

+ References

No definition available.

+ Details

Name:	biib_JointVentureOwnerShipPercentageByThirdParty
Namespace Prefix:	biib_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

- Definition

This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66022249&loc=d3e33749-111570

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name:	us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.

+ References

+ Details

Name:	us-gaap_OtherSalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=biib_BENEPALIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details) $ in Millions, ₩ in Billions	1 Months Ended	3 Months Ended
	Feb. 29, 2012 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2013 USD ($)	Feb. 29, 2012 KRW (₩)
Schedule of Equity Method Investments [Line Items]
Recognized loss		$ 0.0	$ (0.8)
Research and development		437.3	460.5
Revenue related to technical development and technology transfer services		$ 87.9	52.0
Samsung Biosimilar Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals	$ 250.0				₩ 280.5
Variable interest entity, qualitative or quantitative information, ownership percentage	85.00%
Contribution from Biogen to develop, manufacture and market biosimilar pharmaceuticals	$ 45.0				₩ 49.5
Percentage of stake in entity minimum	15.00%	9.00%			15.00%
Percentage of stake in entity maximum	49.90%
Recognized loss			(0.8)
Research and development				$ 46.0
Expected profit share with Samsung Bioepis				50.00%
Revenue related to technical development and technology transfer services		$ 2.7	$ 18.9
BENEPALI
Schedule of Equity Method Investments [Line Items]
Increase in acquired and in-licensed rights and patents		$ 25.0